{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluids&page=48",
    "query": {
      "intervention": "Fluids",
      "page": 48
    },
    "page_size": 10
  },
  "pagination": {
    "page": 48,
    "page_size": 10,
    "total_count": 3553,
    "total_pages": 356,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluids&page=49&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluids&page=47&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T19:32:37.949Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05302765",
      "title": "Intravenous Fluid Administration's Effect on Pediatric Lumbar Puncture",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pediatric Lumbar Puncture"
      ],
      "interventions": [
        {
          "name": "Normal Saline Intravenous Fluids",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Months",
        "maximum_age": "3 Months",
        "sex": "ALL",
        "summary": "0 Months to 3 Months"
      },
      "enrollment_count": 182,
      "start_date": "2022-11-22",
      "completion_date": "2025-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05302765"
    },
    {
      "nct_id": "NCT00575198",
      "title": "Drainage Amount for Removal of Thoracostomy Tube",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pneumothorax",
        "Pleural Effusion"
      ],
      "interventions": [
        {
          "name": "No drainage threshold",
          "type": "OTHER"
        },
        {
          "name": "Drainage <2 mL/kg",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2007-12",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2017-06-21",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00575198"
    },
    {
      "nct_id": "NCT05736367",
      "title": "Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "U-13C-glucose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2024-11-15",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 2,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05736367"
    },
    {
      "nct_id": "NCT03303144",
      "title": "Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Triferic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rockwell Medical Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 27,
      "start_date": "2017-10-01",
      "completion_date": "2017-12-28",
      "has_results": true,
      "last_update_posted_date": "2020-11-16",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03303144"
    },
    {
      "nct_id": "NCT04354064",
      "title": "Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy Volunteer",
        "Prostate Cancer",
        "Head and Neck Cancer",
        "Esophageal Cancer",
        "Genitourinary Cancer",
        "Sarcoma",
        "Breast Cancer",
        "Colon Cancer",
        "Gastrointestinal Cancer",
        "Solid Tumor Cancer",
        "Lung Cancer",
        "Skin Cancer",
        "Melanoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2019-05-29",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04354064"
    },
    {
      "nct_id": "NCT02088398",
      "title": "Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ACY-1215",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acetylon Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2014-03",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-09-11",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02088398"
    },
    {
      "nct_id": "NCT00485134",
      "title": "Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Shigellosis"
      ],
      "interventions": [
        {
          "name": "240 µg Shigella flexneri 2a Invaplex 50 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "480 µg Shigella flexneri 2a Invaplex 50 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "690 Shigella flexneri 2a Invaplex 50 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shigella challenge strain",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 113,
      "start_date": "2007-05",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2017-09-11",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Silver Spring, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00485134"
    },
    {
      "nct_id": "NCT06930664",
      "title": "A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Sotatercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sotatercept Autoinjector",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 85 Years · Female only"
      },
      "enrollment_count": 146,
      "start_date": "2025-05-16",
      "completion_date": "2025-11-25",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Miami, Florida • South Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06930664"
    },
    {
      "nct_id": "NCT05180981",
      "title": "Imaging Brain Fluids During Breathing",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Transcutaneous vagal nerve stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Breathing task",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "Boston University Charles River Campus",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 81,
      "start_date": "2022-01-18",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05180981"
    },
    {
      "nct_id": "NCT05572281",
      "title": "Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tasimelteon Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Tasimelteon Oral Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-05-18",
      "completion_date": "2022-06-15",
      "has_results": false,
      "last_update_posted_date": "2024-03-21",
      "last_synced_at": "2026-11-15T19:32:37.949Z",
      "location_count": 1,
      "location_summary": "Springfield, Missouri",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05572281"
    }
  ]
}